Theo Outlook
Amgen (AMGN) maintains a bullish thesis underpinned by its robust financials in the biopharmaceutical sector. With a market capitalization of $188 billion, trailing P/E of 24.51, forward P/E of 15.85, TTM EPS of $14.23, and quarterly earnings growth of 112% YoY on $36.75 billion TTM revenue (up 8.6% YoY), the stock is positioned for expansion amid strong profitability (profit margin 21%, ROE 68%). Trading near $349 with analyst consensus target of $350.55, it offers moderate upside for moderate-risk investors.
Key catalysts include Amgen's diversified pipeline in oncology, immunology, and rare diseases, driving recent earnings momentum and quarterly revenue beats. Positive analyst sentiment (4 Strong Buy, 9 Buy ratings) and upcoming dividend (yield 2.7%, ex-date May 15, 2026) support shareholder returns. Strategic acquisitions and recombinant DNA innovations position it for market expansion in high-growth therapeutics.
Risks encompass patent expirations on blockbusters, biosimilar competition, and regulatory delays from FDA scrutiny, potentially pressuring margins. Macro headwinds like healthcare policy changes add volatility, though low beta (0.43) provides stability. Mitigations include a strong balance sheet (EBITDA $16.6B), R&D investments, and geographic diversification. Analysis generated by HeyTheo AI based on SEC filings, earnings transcripts, and market data.